Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer

•Final PFS data and second pre-planned interim analysis of OS and safety from J-ALEX.•Sustained improvement in IRF-assessed PFS demonstrated with alectinib.•Superiority of alectinib to crizotinib not concluded at second interim OS analysis.•Fewer alectinib-treated patients experienced grade ≥3 adverse events.•Alectinib continued to demonstrate superiority in IRF-assessed PFS vs crizotinib.